Veracity Capital LLC Purchases 1,446 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Veracity Capital LLC boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 134.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,523 shares of the biotechnology company’s stock after buying an additional 1,446 shares during the period. Veracity Capital LLC’s holdings in United Therapeutics were worth $890,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in UTHR. Benjamin F. Edwards & Company Inc. boosted its holdings in United Therapeutics by 14.0% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock worth $109,000 after buying an additional 42 shares during the period. 1832 Asset Management L.P. purchased a new stake in shares of United Therapeutics during the second quarter worth $1,562,000. Evergreen Capital Management LLC bought a new position in shares of United Therapeutics in the second quarter worth $375,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its position in shares of United Therapeutics by 52.7% in the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 8,565 shares of the biotechnology company’s stock valued at $2,728,000 after purchasing an additional 2,955 shares in the last quarter. Finally, Toronto Dominion Bank grew its position in shares of United Therapeutics by 0.8% in the second quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock valued at $1,441,000 after purchasing an additional 37 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Insider Activity at United Therapeutics

In other news, EVP Paul A. Mahon sold 7,700 shares of the firm’s stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the transaction, the executive vice president now owns 36,710 shares in the company, valued at approximately $13,485,785.60. This trade represents a 17.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $364.91, for a total transaction of $3,649,100.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $940,373.07. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 146,848 shares of company stock valued at $55,165,099 over the last 90 days. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $371.89 on Friday. The company has a market capitalization of $16.60 billion, a P/E ratio of 16.33, a P/E/G ratio of 0.95 and a beta of 0.57. The firm’s 50 day simple moving average is $365.04 and its two-hundred day simple moving average is $355.24. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. During the same quarter in the previous year, the company earned $5.38 EPS. The business’s quarterly revenue was up 22.9% compared to the same quarter last year. On average, sell-side analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on UTHR. Argus upped their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH increased their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. UBS Group lifted their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Finally, HC Wainwright lifted their price target on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $378.36.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.